Profound Medical Corp. (PROF)
NASDAQ: PROF · IEX Real-Time Price · USD
10.22
+0.23 (2.30%)
At close: Jul 19, 2024, 4:00 PM
10.17
-0.05 (-0.49%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Profound Medical Revenue
Profound Medical had revenue of $5.33M in the twelve months ending March 31, 2024, with 2.49% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.40M with 4.20% year-over-year growth. In the year 2023, Profound Medical had annual revenue of $5.41M with 10.99% growth.
Revenue (ttm)
$5.33M
Revenue Growth
+2.49%
P/S Ratio
46.84
Revenue / Employee
$40,688
Employees
131
Market Cap
249.66M USD
Revenue Chart
* The company reports in CAD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.41M | 536.14K | 10.99% |
Dec 31, 2022 | 4.88M | -492.89K | -9.18% |
Dec 31, 2021 | 5.37M | -359.10K | -6.27% |
Dec 31, 2020 | 5.73M | 2.54M | 79.79% |
Dec 31, 2019 | 3.19M | 1.26M | 65.30% |
Dec 31, 2018 | 1.93M | -1.93M | -49.97% |
Dec 31, 2017 | 3.85M | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AirSculpt Technologies | 197.72M |
Codexis | 74.23M |
AVITA Medical | 51.50M |
Utah Medical Products | 49.04M |
Nanobiotix | 40.23M |
Zevra Therapeutics | 28.01M |
Senseonics Holdings | 23.30M |
Atai Life Sciences | 277.00K |
PROF News
- 3 days ago - Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow - GlobeNewsWire
- 11 days ago - Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases - GlobeNewsWire
- 2 months ago - Profound Medical Annual General Meeting of Shareholders Voting Results - GlobeNewsWire
- 2 months ago - Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan - GlobeNewsWire
- 2 months ago - Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum - GlobeNewsWire
- 3 months ago - Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow - GlobeNewsWire
- 3 months ago - Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire
- 4 months ago - Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire